

## SUPPLEMENTARY MATERIALS

**Supplementary Table S1:** Univariate analysis on the association between different nHb values and potential prognostic factors.

Variable \ Nadir Hb	<7.0 g/dL		<8.0 g/dL		<9.0 g/dL		<10.0 g/dL		<11.0 g/dL	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
<i>Demographic parameters and comorbidities</i>										
Age ≥55 years	1.95 (0.90-4.19)	0.09	<b>1.81</b> <b>(1.18-2.79)</b>	<b>0.007</b>	<b>1.87</b> <b>(1.36-2.57)</b>	<b>&lt;0.0001</b>	<b>1.42</b> <b>(1.01-1.98)</b>	<b>0.042</b>	1.36 (0.89-2.07)	0.168
Female sex	0.85 (0.40-1.84)	0.692	0.86 (0.56-1.34)	0.498	1.11 (0.80-1.55)	0.554	<b>1.54</b> <b>(1.09-2.17)</b>	<b>0.016</b>	<b>2.36</b> <b>(1.55-3.60)</b>	<b>&lt;0.0001</b>
Ethnicity (non-Caucasian)	0.77 (0.10-5.89)	1.000	1.47 (0.58-3.71)	0.427	1.27 (0.60-2.72)	0.559	1.79 (0.72-4.49)	0.301	1.71 (0.51-5.76)	0.603
Hypertension	1.59 (0.64-3.98)	0.404	<b>1.82</b> <b>(1.08-3.07)</b>	<b>0.024</b>	<b>1.45</b> <b>(1.02-2.07)</b>	<b>0.042</b>	1.33 (0.93-1.91)	0.135	1.07 (0.68-1.69)	0.815
Hypercholesterolemia	1.27 (0.37-4.36)	0.727	1.59 (0.80-3.14)	0.176	1.34 (0.76-2.36)	0.310	<b>2.51</b> <b>(1.20-5.24)</b>	<b>0.013</b>	2.03 (0.79-5.23)	0.178
Hypothyroidism	1.59 (0.59-4.29)	0.398	1.10 (0.58-2.09)	1.000	1.06 (0.66-1.73)	0.904	1.62 (0.93-2.83)	0.205	1.37 (0.68-2.76)	1.000
Hyperthyroidism	1.87 (0.10-34.63)	1.000	0.47 (0.03-8.63)	1.000	2.19 (0.36-13.21)	0.403	1.92 (0.21-17.29)	1.000	2.24 (0.12-40.79)	0.596
Hyperuricemia	2.71 (0.59-12.40)	0.198	2.05 (0.71-5.87)	0.190	1.87 (0.73-4.79)	0.226	1.26 (0.44-3.58)	0.801	1.64 (0.37-7.22)	0.751
Diabetes mellitus	1.18 (0.27-5.16)	0.689	1.20 (0.51-2.81)	0.649	1.49 (0.77-2.87)	0.238	<b>4.31</b> <b>(1.51-12.33)</b>	<b>0.002</b>	<b>7.85</b> <b>(1.07-57.84)</b>	<b>0.012</b>
Renal diseases	0.38 (0.02-6.47)	0.622	1.32 (0.48-3.58)	0.580	0.98 (0.43-2.21)	1.000	0.85 (0.37-1.96)	0.670	0.80 (0.29-2.18)	0.592
<i>Regular medication</i>										
Statins	1.38 (0.31-6.05)	0.658	1.68 (0.74-3.80)	0.228	1.24 (0.63-2.47)	0.596	<b>2.99</b> <b>(1.14-7.83)</b>	<b>0.024</b>	2.17 (0.65-7.22)	0.246
Painkiller abuse	0.43 (0.06-3.24)	0.715	0.60 (0.23-1.57)	0.408	1.0 (0.55-1.83)	1.000	0.63 (0.34-1.15)	0.145	0.73 (0.35-1.52)	0.417
Blood thinners	2.28 (0.84-6.24)	0.166	1.49 (0.76-2.94)	0.252	1.39 (0.80-2.41)	0.257	1.84 (0.95-3.57)	0.073	1.75 (0.73-4.18)	0.262
<i>Initial SAH severity</i>										
WFNS grade (4-5)	2.14 (0.99-4.60)	0.056	<b>2.85</b> <b>(1.83-4.45)</b>	<b>&lt;0.0001</b>	<b>3.03</b> <b>(2.19-4.21)</b>	<b>&lt;0.0001</b>	<b>3.18</b> <b>(2.21-4.57)</b>	<b>&lt;0.0001</b>	<b>3.27</b> <b>(2.01-5.31)</b>	<b>&lt;0.0001</b>
Fisher grade (3-4)	7.91 (0.48-131.0)	0.063	<b>4.76</b> <b>(1.46-15.46)</b>	<b>0.003</b>	<b>2.58</b> <b>(1.44-4.64)</b>	<b>&lt;0.0001</b>	<b>1.87</b> <b>(1.12-3.15)</b>	<b>0.024</b>	<b>2.14</b> <b>(1.17-3.91)</b>	<b>0.018</b>
Acute hydrocephalus	2.0 (0.68-5.83)	0.265	<b>3.30</b> <b>(1.67-6.51)</b>	<b>&lt;0.0001</b>	<b>3.02</b> <b>(1.98-4.60)</b>	<b>&lt;0.0001</b>	<b>2.83</b> <b>(1.94-4.12)</b>	<b>&lt;0.0001</b>	<b>2.75</b> <b>(1.77-4.26)</b>	<b>&lt;0.0001</b>
Aneurysm size ≥7mm	1.54 (0.72-3.32)	0.333	1.22 (0.80-1.87)	0.383	1.15 (0.83-1.58)	0.417	1.14 (0.81-1.59)	0.496	1.24 (0.81-1.89)	0.338

<i>Clinical events and complications during SAH</i>										
Aneurysm rebleed	2.3 (0.66-8.04)	0.174	1.54 (0.65-3.66)	0.321	1.31 (0.64-2.67)	0.465	2.15 (0.87-5.30)	0.120	1.99 (0.59-6.65)	0.335
Vasospasm	1.63 (0.75-3.51)	0.210	1.44 (0.92-2.27)	0.118	<b>1.74</b> <b>(1.23-2.47)</b>	<b>0.002</b>	<b>2.78</b> <b>(1.82-4.26)</b>	<b>&lt;0.000</b> <b>1</b>	<b>3.58</b> <b>(1.91-6.71)</b>	<b>&lt;0.0001</b>
DC	1.64 (0.77-3.50)	0.218	<b>2.71</b> <b>(1.76-4.18)</b>	<b>&lt;0.00</b> <b>01</b>	<b>3.09</b> <b>(2.18-4.37)</b>	<b>&lt;0.0001</b>	<b>5.32</b> <b>(3.31-8.55)</b>	<b>&lt;0.000</b> <b>1</b>	<b>7.85</b> <b>(3.57-17.24)</b>	<b>&lt;0.0001</b>
ACS	1.36 (0.17-10.7)	0.543	<b>3.0</b> <b>(1.08-8.35)</b>	<b>0.039</b>	2.14 (0.80-5.71)	0.137	2.33 (0.66-8.20)	0.202	1.46 (0.33-6.49)	1.000
Systemic infection	0.91 (0.42-1.97)	0.848	<b>1.71</b> <b>(1.11-2.63)</b>	<b>0.02</b>	<b>2.28</b> <b>(1.63-3.18)</b>	<b>&lt;0.0001</b>	<b>3.23</b> <b>(2.20-4.75)</b>	<b>&lt;0.000</b> <b>1</b>	<b>3.92</b> <b>(2.27-6.77)</b>	<b>&lt;0.0001</b>
Clipping	0.64 (0.29-1.42)	0.335	<b>1.79</b> <b>(1.17-2.73)</b>	<b>0.008</b>	<b>2.44</b> <b>(1.76-3.37)</b>	<b>&lt;0.0001</b>	<b>4.22</b> <b>(2.86-6.24)</b>	<b>&lt;0.000</b> <b>1</b>	<b>6.99</b> <b>(3.75-13.05)</b>	<b>&lt;0.0001</b>

Abbreviations: Hb=hemoglobin, OR= odds ratio, CI= confidence interval, WFNS= World Federation of Neurosurgical Societies, DC= decompressive craniectomy, ACS= acute coronary syndrome. Significant results are in bold.

**Supplementary Table S2:** Multivariate analysis with the M1 (adjusted for baseline characteristics) and M2 models on the association between different nHb values and the major outcome endpoints of the study.

Nadir Hb:		<7.0 g/dL		<8.0 g/dL		<9.0 g/dL		<10.0 g/dL		<11.0 g/dL	
		OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
<i>Cerebral infarctions</i>	MVA M1	1.29 (0.58 - 2.87)	0.530	1.54 (0.96 - 2.46)	0.073	<b>1.72</b> <b>(1.21 - 2.46)</b>	<b>0.003</b>	<b>2.47</b> <b>(1.66 - 3.68)</b>	<b>&lt;0.0001</b>	<b>2.30</b> <b>(1.38 - 3.84)</b>	<b>0.001</b>
	MVA M2	1.28 (0.56 - 2.96)	0.557	1.33 (0.82 - 2.17)	0.249	<b>1.70</b> <b>(1.16 - 2.50)</b>	<b>0.007</b>	<b>1.83</b> <b>(1.19 - 2.81)</b>	<b>0.006</b>	1.67 (0.98 - 2.86)	0.062
<i>Unfavorable outcome at 6 months</i>	MVA M1	1.98 (0.80 - 4.92)	0.142	<b>2.85</b> <b>(1.65 - 4.92)</b>	<b>&lt;0.0001</b>	<b>3.05</b> <b>(2.04 - 4.56)</b>	<b>&lt;0.0001</b>	<b>2.19</b> <b>(1.39 - 3.46)</b>	<b>0.001</b>	<b>2.17</b> <b>(1.18 - 3.98)</b>	<b>0.013</b>
	MVA M2	1.98 (0.74 - 5.34)	0.176	<b>2.21</b> <b>(1.21 - 4.04)</b>	<b>0.010</b>	<b>2.44</b> <b>(1.57 - 3.79)</b>	<b>&lt;0.0001</b>	1.50 (0.89 - 2.52)	0.126	1.43 (0.75 - 2.72)	0.280
<i>In-hospital mortality</i>	MVA M1	2.43 (0.64 - 9.21)	0.193	<b>3.32</b> <b>(1.62 - 7.23)</b>	<b>0.003</b>	<b>4.84</b> <b>(2.49 - 9.41)</b>	<b>&lt;0.0001</b>	<b>9.61</b> <b>(4.08 - 22.62)</b>	<b>&lt;0.0001</b>	<b>7.41</b> <b>(2.74 - 20.04)</b>	<b>&lt;0.0001</b>
	MVA M2	2.20 (0.50 - 9.68)	0.298	<b>2.44</b> <b>(1.07 - 5.55)</b>	<b>0.034</b>	<b>3.22</b> <b>(1.59 - 6.51)</b>	<b>0.001</b>	<b>6.06</b> <b>(2.39 - 15.34)</b>	<b>&lt;0.0001</b>	<b>4.60</b> <b>(1.61 - 13.14)</b>	<b>0.004</b>

Abbreviations: OR= odds ratio, CI= confidence interval. Significant findings are in bold.

**Supplementary Table S3:** Analysis of the association between the timing of outcome-relevant nHb <9.0 g/dL and the major study endpoints.

nHb < 9.0 g/dL		Begin			Duration		
		Median (days)	95% CI	p-value	Mean (days)	SD	p-value
<i>Cerebral infarctions</i>	yes	6	4.58-7.00	0.504	4	4	0.488
	no	5	4.00-6.67		5	5	
<i>Unfavourable outcome at 6 months</i>	yes	5	4.00-6.00	0.382	4	5	0.662
	no	5.4	4.00-7.00		4	5	
<i>In-hospital mortality</i>	yes	<b>3.9</b>	<b>2.23-5.00</b>	<b>0.001</b>	<b>3</b>	<b>3</b>	<b>0.041</b>
	no	<b>6</b>	<b>5.67-7.60</b>		<b>5</b>	<b>5</b>	

Abbreviations: CI = confidence interval, SD = standard deviation. Significant findings are bold.